The right sex hormones do indeed strongly prevent heart disease developing in women.

When the WHIMs study was cancelled prematurely, the public generally believed it was due to a perceived increase in breast cancer risk.  This is not true.  There was no significant increase in breast cancer in this study, but they were seeing a lack of heart disease protection, & this was the actual reason given for the study's premature stoppage.  Stopping a clinical study prematurely is a real no-no.  Imagine if I did a weather study starting in October and concluded in late February that the world was going to continue getting colder & colder instead or cycling back to summer.  What a fool I would be.

The antiquated oral hormones used in the WHIMS trial increased clot-related disease & failed to prevent heart disease because of their individual qualities, qualities not shared by non-oral human estradiol.  Human estradiol, when delivered expertly, in an adequate dosage and at a steady non-erratic flow clearly, & to a remarkable degree reduces heart disease events.  It does so by altering the principal risk factors for organic heart disease.  This includes lowering insulin resistance, reducing high blood pressure, & lowering the levels of bad cholesterol while also blocking their negative influence. Yet despite all of these benefits,  the FDA insists on non-oral estradiol being harnessed with the same warning labels & caveats as are applied to oral hormones.